Real-world efficacy and safety of two doses of cabazitaxel (20 or 25 mg/m2) in patients with castration-resistant prostate cancer: results of a Japanese post-marketing surveillance study

Peer Review reports

Original Submission
12 Mar 2020	Submitted	Original manuscript
24 Mar 2020	Author responded	Author comments - Hideyasu Matsuyama
Resubmission - Version 2
24 Mar 2020	Submitted	Manuscript version 2
18 Apr 2020	Reviewed	Reviewer Report - Arun Azad
3 May 2020	Reviewed	Reviewer Report - Roberto Bordonaro
26 Jun 2020	Author responded	Author comments - Hideyasu Matsuyama
Resubmission - Version 3
26 Jun 2020	Submitted	Manuscript version 3
30 Jun 2020	Author responded	Author comments - Hideyasu Matsuyama
Resubmission - Version 4
30 Jun 2020	Submitted	Manuscript version 4
Publishing
2 Jul 2020	Editorially accepted
13 Jul 2020	Article published	10.1186/s12885-020-07131-6

Back to article page